Publication of Annual Report 2020
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Acacia Pharma Group plc Publishes its Annual Report and Financial Statements for the Year ended 31 December 2020
Cambridge, UK and Indianapolis, US – 30 March 2021, 07:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the publication of its Annual Report and Financial Statements for the Year ended 31 December 2020.
The Annual Report is attached here and also available on www.acaciapharma.com in the Investors/Financial Reports and Presentations section.
Contacts
| Acacia Pharma Group plc Mike Bolinder, CEO Gary Gemignani, CFO +44 1223 919760 / +1 317 505 1280 IR@acaciapharma.com
|
International Media Mark Swallow, Frazer Hall, David Dible Citigate Dewe Rogerson +44 20 7638 9571 acaciapharma@citigatedewerogerson.com |
| US Investors LifeSci Advisors Irina Koffler +1 917-734-7387 ikoffler@lifesciadvisors.com |
Media in Belgium and the Netherlands Chris Van Raemdonck +32 499 58 55 31 chrisvanraemdonck@telenet.be |
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.
Acacia Pharma’s first product, BARHEMSYS® (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV).
BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.
Acacia Pharma Group plc
The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376
Attachment